Vivoryon Therapeutics Eulerpool Ziņas

Vivoryon Therapeutics Eulerpool News

Vivoryon Therapeutics Akciju Ziņas

Vivoryon Therapeutics tiek uzmanīgi vēroti no žurnālistu un investoru puses visā pasaulē. Jaunākās Vivoryon Therapeutics ziņas mēs apkopojam šeit.

• 12. septembris ·

  Yahoo
  Vivoryon Therapeutics N.V. Reports H1 2024 Progress Marked by Compelling Kidney Function Data and Execution of Strategy to Advance Varoglutamstat in Kidney Disease
• 5. septembris ·

  Yahoo
  Vivoryon Therapeutics N.V. Announces Completion of Share Capital Reduction and Change to Articles of Association
• 5. septembris ·

  Yahoo
  Vivoryon Therapeutics N.V. to Report Half Year 2024 Financial Results on September 12, and to Host KOL Event on September 30, 2024
• 13. augusts ·

  Yahoo
  Here's Why We're Watching Vivoryon Therapeutics' (AMS:VVY) Cash Burn Situation
• 18. jūlijs ·

  Yahoo
  Vivoryon Therapeutics N.V. Announces New Data Showing Unique Treatment Effects of Varoglutamstat on Kidney Function in Patients with Diabetes and Outlines Proposed Clinical Development Plan in Diabetic Kidney Disease
• 9. jūlijs ·

  Yahoo
  Vivoryon Therapeutics N.V. to Host R&D Update Call on July 18, 2024 Focused on Progress in Kidney Disease
• 21. jūnijs ·

  Yahoo
  Vivoryon Therapeutics N.V. Reports Outcome of 2024 Annual General Meeting
• 23. maijs ·

  Yahoo
  Vivoryon Therapeutics N.V. Reports Q1 2024 Financial Results and New Data Reinforcing Strategic Focus in Kidney Disease
• 22. maijs ·

  Yahoo
  When Will Vivoryon Therapeutics N.V. (AMS:VVY) Become Profitable?
• 15. maijs ·

  Yahoo
  Vivoryon Therapeutics N.V. to Report Q1 2024 Financial Results and Operational Progress on May 23, 2024